DHC Pediatric Webinar - Neurofibromatosis Type 1 Update

Tuesday, December 10, 2024, 8:00 AM - Friday, December 10, 2027, 9:00 AM

AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hours (1.00 hours), CME-Designated Participation Credit (1.00 hours)

This Pediatric Lecture Series will discuss important pediatric topics that may lead to the improvement of child health from an individual, health care system and/or societal level.

Presenters

Deborah Rukin Gold, MD
Section Chief, Pediatric Neurology
Dartmouth Health, Lebanon, NH 
* Pediatric Residency at Rainbow Babies and Children’s Hospital, Cleveland, OH
* Child Neurology Fellowship and Pediatric Neuro-Oncology Training at the Cleveland Clinic
* Previously worked at Rainbow Babies and Children’s Hospital 2002 – 2023 before joining Dartmouth in September 2023

Nadine P. SantaCruz, MD, MPH
Pediatric Hematology and Oncology
Dartmouth Health, Lebanon, NH
* Pediatric residency at Kaiser Oakland
* Pediatric hematology Oncology Fellowship at Hasbro Children’s hospital in Rhode Island
* Pediatric neuro oncology fellowship at Boston Children’s/Dana-Farber
* Previously was the chair of pediatric oncology at Eastern Maine medical center prior to joining Dartmouth last year.

1. Identify common signs and symptoms of neurofibromatosis type 1.
2. Describe the need for multi-disciplinary care of the child with neurofibromatosis type 1 including the increased awareness of current care at DHMC
3. Discuss newer strategies for diagnosis and management of children with neurofibromatosis type 1.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours.

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.
2. Register for the activity.
3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.
4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).
5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.
6. Complete and Submit the Evaluation.

Bibliographic Material

• Thatcher et al. Sci Signal 2010;3(119)
  
  
• Legius et al Genet Med 2021;23, 1506–1513
  
  
• Williams et al. Pediatrics 2009;123(1):124-133
  
  
• Miller et al Pediatrics: 2019; 143(5)
  
  
• Nguyen et al. Pediatrics 2011;159(4):652-658
  
  
• Kim et al. Neurology 2009;73(16):1273-1279
  
  
• Dombi et al Neurology 2007;68(9):643-647
  
  
• Gross et al Neuro Oncol 2018;20(12):1643-1651
  
  
• Mautner et al Neuro Oncol 2008;10(4):593-598
  
  
• Needle et al J Pediatr 1997;131(5):678-682
  
  
• Copley-Merriman et al Adol Health Med Ther 2021;12:55-66
  
  
• Fisher et al Neuro Oncol 2022;24(11):1827-1844
  
  
• FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease, FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease | FDA
  
  
• Dombi et al. NEJM 2016; 375:2550-2560
  
  
• Gross et al. N Engl J Med 2020;382:1430-1442
  
  
• Gross et al. Neuro Oncol. 2022;24(11):1978-1988
  
  
• deBlank et al J Neuroophthalmol 2017;37:S23-S32
  
  
• ?Listernick et al Ann Neurol 2007;61(3):189-198
  
  
• Fisher et al Neuro Oncol 2012;14:790-797
  
  
• Ater et al Cancer 2016;122:1928-1936
  
  
• Fisher et al Neuro Oncol 2012;14:790-197
  
  
• Banerjee et al Neuro-Oncol 2016;19(8):1135-1144
  
  
• Fangusaro J et al. Lancet Oncol 2019; 20: 1011-1022
  
  
• clinicaltrials.gov; CTF.org announcement
  
  
• Walsh et al Neurol Genet 2021;7(5):e616
  
  
• Klesse et al The Oncologist 2022;25:e1109-e1116
  
  
• DeBlank et al Neuro Oncol 2022;24(11):1845-1856
  
  
• Griffiths et al. Pediatrics 1999;104:1-8
  
  
• David T. Miller, MD; Debra Freedenberg, MD; Elizabeth Schorry, MD; Nicole J. Ullrich, MD; David Viskochil, MD; Bruce R. Korf, MD; COUNCIL ON GENETICS;AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS; Emily Chen, MD; Tracy L. Trotter, MD; Susan A. Berry, MD; Leah W. Burke, MD; Timothy A. Geleske, MD; Rizwan Hamid, MD; Robert J. Hopkin, MD; Wendy J. Introne, MD; Michael J. Lyons, MD; Angela E. Scheuerle, MD; Joan M. Stoler, MD From the American Academy of Pediatrics| Clinical Report| May 01 2019 Health Supervision for Children With Neurofibromatosis Type 1 Volume 143, Issue 5; Pediatrics (2019) 143 (5): e20190660. https://doi.org/10.1542/peds.2019-0660
  
  

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.